The Federal Food, Drug, and Cosmetic Act (FD&C Act) gives the Food and Drug Administration authority to regulate food, drugs, and medical devices, among other products. New provisions are added from time to time—or existing ones enhanced or expanded—to enable the agency to better do its job.
Congressional support grows for FDA regulation of tobacco in US. Bill now sponsored by 55 senators, 200 representatives in America. The following is a statement of William V. Corr, Executive Director, Campaign for Tobacco-Free Kids:
The first reported findings from an international, Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75).
Several new studies suggest how transplant surgeons can make more effective use of kidneys from deceased donors — even those that are at the outer limits of acceptance criteria — according to researchers from Wake Forest University Baptist Medical Center.
One in four people who are chronically infected with hepatitis B will die from its impact if untreated, but a team of researchers at the Stanford University School of Medicine has identified the most cost-effective way of fighting this treacherous infection.
Today’s announcement of the planned 2008 increase in Medicare premiums underscores the urgent need for congressional action on Medicare, says the American Medical Association (AMA). In CMS’ analysis of the premium increase, it is clear that growth in Medicare Advantage plans is solely responsible for the increase in the 2008 Medicare Part B premium.
The 58th International Astronautical Congress is taking place this week from Sept. 24 to 29 in Hyderabad, India, with the theme “Touching Humanity: Space for Improving Quality of Life.”
“Thank you, and good morning. I’m Dr. Edward Langston, Board Chair of the American Medical Association and a family physician in Lafayette, Indiana. I’m pleased to be here today to represent the nation’s largest physician organization as part of this diverse group of voices supporting children’s health care.
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).
A report on the State Children’s Health Insurance Program (SCHIP) showing increases in program enrollment, coverage, and access to health care among low-income, uninsured children was released today by the Centers for Medicare & Medicaid Services (CMS).